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Abstract
We are not aware of a report detailing the complex obstetrical and medical management of twin pregnancy in the context
of HIV infection and early post-liver transplantation period. Here we describe the successful outcome of a twin pregnancy
in a 28-year-old HIV-positive female receiving antiretroviral therapy and immunosuppressive therapy who was the recipient
of a liver transplant for previous drug-induced liver failure.
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Introduction
Liver and kidney transplantations are now more commonly
performed in the HIV patient population [1,2]. There is evidence
from centres in the US and Europe to suggest that the 1–5-year
survival following liver transplantation in those infected with HIV
is comparable to HIV-seronegative individuals [3,4]. As the number
of individuals living with long-term HIV infection continues to rise,
the need for transplantation may be expected to increase in both
male and female patients [5–7]. Currently, there is limited
information in the literature on pregnancy outcome in the setting
of liver transplantation and HIV infection [8].
Case report
A 28-year-old Zimbabwean-born female was originally diagnosed
with HIV infection in 2003 at 32 weeks of her first pregnancy.
She was commenced on antiretrovirals (ART) at this time with a
protease inhibitor-based regimen, and gave birth to an uninfected
infant. Treatment for HIV infection was discontinued after
pregnancy as she had a preserved CD4 T cell count. In January
2012 treatment was re-started with a single-tablet combination
of tenofovir, emtricitabine and efavirenz. In July she was admitted
to her local hospital with deranged liver function tests (LFTs) on
a background of a 1-month history of jaundice and dark urine,
at which stage ART was discontinued.
She was subsequently transferred to the Liver Unit at the Royal
Free Hospital, London in August 2012 for her ongoing
management. At the time of the transfer her LFTs were abnormal
and INR was at 4.2 (range: 0.9–1.2). Despite medical management,
her liver dysfunction progressed and she developed grade 3 hepatic
encephalopathy (Figure 1). The assumed diagnosis was acute liver
injury secondary to efavirenz. She met the King‘s College non-
acetaminophen poor prognostic criteria, and was super-urgently
listed for, and subsequently underwent, liver transplantation (LT).
Histology was consistent with fulminant hepatitis with bridging
and extensive confluent necrosis, ductular reaction and mixed
inflammation. There was massive architectural collapse with
moderate hepatocellular and canalicular cholestasis. No viral
inclusions or ground-glass cells could be seen and special stains
did not reveal significant background fibrosis or cirrhosis. At the
time of transplantation her HIV viral load was <40 copies/mL with
a CD4 T cell count of 173 cells/mm3, which had decreased acutely
during this period (Figure 2A, B). She had an uneventful post-LT
recovery and was discharged 3 weeks later on tenofovir 245 mg
daily, emtricitabine 200 mg daily and raltegravir 400 mg twice daily
for HIV control, and tacrolimus, azathioprine and prednisolone as
immunosuppressive therapy [9].
The patient conceived naturally at 7 months post-LT. At this time,
she had normal LFTs, an undetectable HIV viral load and preserved
CD4 T cell count (Figures 1, 2). A dichorionic, diamniotic twin
pregnancy was diagnosed by ultrasound (US) scan and her care
was facilitated via a multidisciplinary team including HIV physicians,
obstetricians, midwives and hepatologists at the Royal Free
Hospital, London. At approximately 8 weeks’ gestation (April 2013)
elevated serum aminotransferases were noted (Figure 1) and the
patient was admitted for further investigations. An acute hepatitis
viral screen was negative. On admission (9 May 2013) her
tacrolimus level was 4.5 μg/mL (range: 5–15) but normal on
discharge (10 May 2013) at 5.5 μg/mL. There was no change
made to her tacrolimus dose. A liver US scan revealed patent
hepatic vasculature with no evidence of biliary dilatation. A liver
biopsy taken at the end of the first trimester revealed normal
hepatic architecture with a mild, predominantly lymphoplasmocytic
inflammatory infiltrate in a few portal tracts along with scattered
eosinophils. There was no bile duct damage or endotheliitis. These
findings were consistent with mild hepatitic features, the cause
of which was not evident morphologically. There were no diagnostic
features of acute cellular rejection (ACR). The tacrolimus level was
at 4.8 μg/mL on 29 May 2013 and 3.7 μg/mL on 31 May 2013
during her admission. Liver enzymes remained elevated from the
10th until the 20th week of pregnancy, at which time they
normalised (Figure 1).
At 27 weeks’ gestation the patient developed acute kidney injury
with an increased creatinine (maximum level of 166 μmol/L), which
resolved spontaneously by 30 weeks, after hospital admission. She
was reviewed by the Renal team and no identifiable cause was
found. Serum creatinine increased again at 34 weeks’ gestation,
with a concomitant rise in blood pressure. The patient was closely
monitored at this stage for pre-eclampsia and underwent a
semi-emergency Caesarean section at 35 weeks’ gestation under
general anaesthetic, in view of her rising blood pressure and
deteriorating renal function. Steroids were administered at the end
of pregnancy to avoid respiratory distress of the newborns. The
patient delivered two healthy HIV-negative infants with no
evidence of compromise to the mother in terms of the control
of her HIV infection or liver graft function (Figures 1, 2). The
newborns had good birth weights (Twin 1 of 2110 grams and Twin
2 of 2032 grams) and were admitted into the neonatal unit at
birth and discharged after 3 weeks.
The mother remained on the same ART regimen and
immunosuppressive therapy post-delivery. Of note, close
monitoring of tacrolimus levels and liver and renal function had
been required at regular intervals throughout her pregnancy. The
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tacrolimus dose required reduction post-delivery and the patient
was discharged on 4 mg twice daily and azathioprine.
Discussion
We report on the successful outcome of a twin pregnancy in an
HIV-positive patient on antiretroviral and immunosuppressive
therapy (tacrolimus and azathioprine) with a history of recent liver
transplantation for acute liver failure secondary to ART drug
toxicity. The complexity of the management of such a case was
highlighted by the involvement of several specialist teams within
the same hospital, such as HIV physicians, transplant surgeons,
liver specialists and HIV-dedicated obstetricians and midwives.
Although there was an overall positive outcome for both the
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Figure 1. Liver enzymes (LFTs) and function (INR) measured over the timeline of patient management: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were
measured during times of patient admission and in the outpatient setting. Marked derangement in LFTs and INR was observed at the time of liver transplantation. At
conception, LFTs and INR were normal. During the first trimester a rise in LFTs was present although INR remained normal throughout pregnancy. A liver biopsy was
performed during the period of LFTs derangement. Caesarean section was performed at gestational age of 35 weeks+0 days
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Figure 2. HIV viral load and CD4 cell count measured over the timeline of patient management: HIV viral load (A) and CD4 count (B) were monitored periodically from the time of
patient transfer. The patient‘s HIV infection remained well controlled throughout pregnancy
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mother and babies, the patient required intensive monitoring,
particularly with regards to the control of her HIV infection, liver
transplant and renal function. She required multiple admissions
for deranged LFTs resulting in a liver biopsy to exclude an acute
rejection episode and monitor her renal function and blood
pressure in the later stages of pregnancy. A semi-urgent Caesarean
section was performed for the management of hypertension and
deteriorating renal function.
Previous studies have confirmed the complex management and
risks associated with pregnancy in LT recipients [10–13]. Although
a successful outcome for the mother, baby and graft can be
expected in the majority of cases, with a reported live birth rate
of up to 80%, there remain concerns regarding an increased risk
of ACR, maternal infections, gestational diabetes, renal impairment
and pre-eclampsia. In terms of the fetus there is a risk of
prematurity (30%) and intra-uterine growth restriction [10,13].
It is now widely accepted amongst LT physicians that pregnancy
post-LT should be delayed for 12 months. This is due to increasing
data showing that pregnancies within 12 months of LT are
associated with a significant and prohibitive increased risk of ACR
[10]. Whilst most ACR cases in conjunction with pregnancy can
be controlled with augmentation of baseline immunosuppression,
graft loss and the need for re-transplantation have been reported
[10,13,14].
The experience in managing the case described here is consistent
with findings of these studies in that a decline in both liver and
renal functions was observed and required a liver biopsy and
semi-emergency Caesarean section, respectively. Of note, a good
birth weight was observed for the twin newborns and both the
mother and infants remain well to date. Furthermore, the findings
of Westbrook et al. and other case series [10] note that therapy
with calcineurin inhibitors is safe in pregnancy and should be
continued, as was the case with our experience in this patient.
Due to the risk of multiple complications in solid organ recipients
when pregnant, a multidisciplinary approach remains pivotal in
order to prevent or manage such cases, in terms of antiretroviral
therapy, immunosuppression, graft function and antenatal care.
The timing of a liver biopsy and the management of the patient
during the period of increasing LFTs in the first trimester of
pregnancy required regular interactions between multiple specialist
teams, including for the decision to delay biopsy until the second
trimester. However, there are no data to suggest that a liver biopsy
is harmful in pregnancy via the ultrasound-guided route.
Most series of LT in HIV infection involve patients who are
co-infected with hepatitis B or C [2,7]. This is due to the increased
risk of co-infected HIV patients developing decompensated chronic
liver disease. Liver transplantation for HIV in isolation is a relatively
rare phenomenon, with the indication being acute liver failure
secondary to an idiosyncratic drug reaction to HIV therapy [6,7,15]
To conclude, this case report highlights the fact that pregnancy
post LT is a realistic option for women who are infected with HIV.
It clearly stresses the importance of adopting a multidisciplinary
approach for all aspects of patient care throughout pregnancy and
regular monitoring of maternal and fetal progress. This transplant
recipient remained clinically stable with a favourable outcome for
a twin pregnancy. The patient was successfully managed through
episodes of increased LFTs with liver biopsy as well as blood
pressure increase with deteriorating renal function consistent with
pre-eclampsia, leading to a semi-urgent Caesarean section which
resulted in the birth of two healthy HIV-negative infants of
preserved birth weight. There was no evidence of compromise to
the control of the patient‘s HIV infection or of graft rejection.
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